Skip to main content

Table 1 Demographic and clinical characteristics evaluated during the 12-month baseline period

From: Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study

 Non-CID cohort (not diagnosed with RA, PsA, PsO or AS)All patients: RA, PsO, PsA, or AS cohortPatients with RAPatients with PsO and PsAPatients with PsO but without PsAPatients with ASPatients with AS, PsO or PsA
(N = 1,008,436)(N = 537,450)(N = 206,260)(N = 21,250)(N = 124,950)(N = 16,029)(N = 183,318)
Agea, mean ± SD46.3 ± 16.354.0 ± 14.757.5 ± 13.751.4 ± 12.251.1 ± 15.149.4 ± 13.851.3 ± 14.4
Female, %55.1%63.1%75.8%52.8%51.5%43.8%51.3%
Payment type, %
 Commercial88.9%79.3%73.6%89.0%83.6%88.3%84.9%
 Medicare11.1%20.7%26.4%11.0%16.4%11.7%15.1%
Region of residencea, %
 South39.0%37.5%39.1%40.2%36.2%36.3%36.8%
 North Central21.9%22.4%23.0%20.2%22.4%19.1%21.7%
 West18.9%16.8%16.5%17.6%16.7%24.9%17.4%
 North East18.9%22.4%20.5%21.0%24.0%18.9%23.2%
 Unknown1.4%0.8%0.8%1.1%0.8%0.8%0.9%
Year of index date, %
 201130.9%24.8%28.2%23.4%26.0%25.7%25.9%
 201219.2%17.8%17.5%14.4%17.8%16.6%17.4%
 201316.8%15.8%15.1%14.6%15.6%14.8%15.4%
 201413.0%13.4%12.3%13.4%13.5%12.5%13.3%
 201516.9%16.0%14.5%19.1%15.8%16.9%16.2%
 20163.3%12.2%12.4%15.1%11.3%13.5%11.9%
Quan-Charlson Comorbidity Indexb, mean ± SD0.5 ± 1.11.2 ± 1.51.9 ± 1.40.9 ± 1.30.7 ± 1.20.9 ± 1.30.7 ± 1.3
Extra-articular manifestationsb,c, %12.4%43.5%27.3%100.0%100.0%32.5%84.8%
Gastro-related conditionsb,d, %13.6%18.8%22.1%19.5%15.3%22.5%16.7%
Drug useb, %
 NSAIDS17.0%33.3%43.7%42.5%20.5%51.5%28.3%
 Corticosteroids19.5%45.3%62.3%49.3%33.4%47.7%38.2%
 Biologics0.1%21.0%31.9%54.3%16.4%44.9%27.0%
 PDE4 inhibitors0.0%0.4%0.1%3.2%0.9%0.1%1.2%
 Opioids24.0%38.8%50.0%42.3%27.6%50.0%33.1%
 DMARDs1.5%37.6%67.1%56.4%17.4%39.4%28.8%
  1. CID Chronic inflammatory disease, SD Standard deviation, HRU Healthcare resource utilization, RA Rheumatoid arthritis, PsA Psoriatic arthritis, PsO Psoriasis, AS Ankylosing spondylitis, NSAIDs Non-steroidal anti-inflammatory drugs, DMARDS Disease modifying anti-rheumatic drugs
  2. aMeasured at the index date.
  3. bMeasured during the 12-month baseline period.
  4. cExtra-articular manifestations include cutaneous, ocular, cardiovascular, urogenital, pulmonary, and other manifestations such as enthesopathies, parapsoriasis, pityriasis, and other psoriasis and similar disorders.
  5. dGastro-related conditions include diarrhea, weight loss, blood in stool, abdominal pain, gastrointestinal hemorrhage, ischemic colitis, dyspepsia, and gastroenteritis.